May 10, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Dorrie Yale | |
| Re: | ARCA biopharma, Inc. | |
| Registration Statement on Form S-3 | ||
| File No. 333-217459 | ||
| Acceleration Request | ||
| Requested Date: Friday, May 12, 2017 | ||
| Requested Time: 4:00 P.M. Eastern Daylight Time | ||
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-217459) (the “Registration Statement”) to become effective on May 12, 2017, at 4:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Brent Fassett of Cooley LLP, counsel to the Registrant, at (720) 566-4025, or in his absence, Nathan Jeffries at (720) 566-4104.
[Signature page follows]
| Very truly yours,
ARCA BIOPHARMA, INC. | ||
| By: | /s/ Brian L. Selby | |
| Brian L. Selby Vice President, Finance | ||
cc: Brent Fassett, Cooley LLP